OPPM
ELDN icon

Opus Point Partners Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Opus Point Partners Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-383
Closed -$541K – 54
2015
Q4 		$541K Buy
+383
New +$667K 0.36% 51

Other funds holding ELDN

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Opus Point Partners Management's ELDN Position: Q1 2016 in Review

Opus Point Partners Management sold out of Eledon Pharmaceuticals (ELDN) in Q1 2016, closing a stake of 383 shares — an estimated $541K sold.

Opus Point Partners Management first reported a position in ELDN in Q4 2015 and held it in 1 quarter. The position peaked at $541K in Q4 2015. 49 funds tracked by Wall St. Rank hold ELDN as of Q1 2016.

  • Opus Point Partners Management reported no remaining Eledon Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Opus Point Partners Management sold 383 Eledon Pharmaceuticals shares in Q1 2016, an estimated $541K.
  • Opus Point Partners Management first reported a position in Eledon Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Opus Point Partners Management's Eledon Pharmaceuticals position peaked at $541K in Q4 2015.
  • 49 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2016.

Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.